Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain

Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain

Current guidelines recommend temozolomide as the first-line chemotherapy for aggressive pituitary neuroendocrine tumours. However, no clinical trials have been conducted to date and clinical experience is quite limited. We retrospectively analyzed 28 patients (9 women and 19 men), aged 46.6 + 16.9,...

Full description

Bibliographic Details
Main Authors: Cristina Lamas, Rosa Cámara, Carmen Fajardo, Pablo Remon-Ruiz, Betina Biagetti, Fernando Guerrero-Pérez, Marta Araujo-Castro, Mireia Mora, Felicia Hanzu, Pedro Iglesias, Rogelio García-Centeno, Alfonso Soto
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Endocrinology
Subjects:
temozolomide
pituitary neuroendocrine tumor
pituitary carcinoma
aggressive pituitary tumor
radiotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1204206/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.1204206/full

Similar Items